U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07231939) titled 'Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI' on Sept. 29.
Brief Summary: All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.
The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available.
The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic p...